Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company based in Malvern, Pennsylvania, has entered a collaboration with Weave Bio to support preparation of its planned New Drug Application (NDA) for buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). The announcement, detailed in a recent press release, highlights the company's strategic use of artificial intelligence to streamline regulatory documentation while maintaining rigorous human oversight.
Under the collaboration, Annovis will deploy the Weave AI platform to draft, review, and manage NDA documents. Importantly, the company's regulatory and clinical teams will retain full responsibility for the content, verification, and final approval of all materials submitted to the U.S. Food and Drug Administration (FDA). This approach aims to expedite the NDA preparation process without compromising accuracy or compliance. The move comes on the heels of Annovis completing enrollment in its pivotal Phase 3 AD study, which enrolled 862 biomarker-confirmed patients, surpassing the original target of 760. The company is targeting a database lock for the six-month treatment period in December 2026, followed by top-line symptomatic data in March 2027. By preparing most of the NDA before the data readout, Annovis hopes to position itself for a faster submission timeline if the trial results are positive.
The implications of this collaboration extend beyond Annovis. If successful, it could demonstrate how AI can be responsibly integrated into regulatory workflows, potentially setting a precedent for other biotechnology firms seeking to accelerate drug development. For patients with Alzheimer's and Parkinson's, diseases with significant unmet needs, faster NDA preparation could mean earlier access to new therapies. Buntanetap, formerly posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions. The company's progress is closely watched by investors and industry analysts, with updates available in its newsroom at https://ibn.fm/ANVS.
Annovis Bio is publicly traded on the New York Stock Exchange under the ticker ANVS. The company's lead drug candidate targets multiple neurodegenerative diseases, and the current collaboration with Weave Bio underscores its commitment to innovation in regulatory affairs. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The news was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers services including wire distribution through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. These platforms help ensure that news like Annovis's collaboration reaches a wide audience of investors and industry stakeholders.
